ENGN.NASDAQEngene Holdings INC
10-K/A: enGene Holdings Files Amendment No. 1 to Form 10-K to Include Part III Information
Sentiment:
Form 10-K/A Amendment
enGene Holdings Inc. files an amendment to its annual report on Form 10-K to include previously omitted Part III information regarding directors, executive officers, and corporate governance.
Summary
- enGene Holdings Inc. is filing Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended October 31, 2024.
- The amendment includes Part III information previously omitted in reliance on General Instruction G(3) to Form 10-K.
- The amendment restates Part III, Items 10, 11, 12, 13, and 14, and Part IV, Item 15 of the Original Form 10-K.
- The amendment includes new certifications of the principal executive officer and principal financial officer.
- No other items of the Original Form 10-K have been amended or revised.
- The document includes information about the company's directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees and services.
- As of February 14, 2025, the number of the registrant's Common Shares outstanding was 50,977,560.
- The aggregate market value of the common equity held by non-affiliates of the Registrant, based on the closing price of the Common Shares on The Nasdaq Stock Market LLC on April 30, 2024 was $533,605,876.
Sentiment
Score: 6
Explanation: The document is a regulatory filing and is primarily factual. The sentiment is neutral, with a focus on providing required information.
Positives
- The company has a code of business conduct and ethics applicable to all directors, officers, and employees.
- The company has an insider trading policy to promote compliance with insider trading laws.
- The company has established an audit committee, a compensation committee, and a nominating and corporate governance committee.
- The company has entered into indemnification agreements with its directors and certain executive officers.
- The company maintains a US tax-qualified retirement plan and a Canadian tax-qualified retirement plan for eligible employees.
Risks
- The document contains forward-looking statements that are subject to various risks and uncertainties.
- The company is heavily dependent on the success of detalimogene.
- The company is subject to extensive regulation of all aspects of its business.
- The company faces competition from other existing or newly developed products and treatments.
- The company's ability to raise additional capital to fund its product development activity is a risk.
- The company's ability to maintain key relationships and to attract and retain talented personnel is a risk.
- Changes in domestic and foreign business, market, financial, political, geopolitical, legal conditions and laws and regulations could adversely affect the company.
- The risk that any regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the company.
Future Outlook
The document contains forward-looking statements regarding the company's expectations, hopes, beliefs, intentions, goals, and strategies regarding the future, including financial performance, recruitment and retention of personnel, ability to manage executive transitions, and ability to implement and maintain effective internal controls.
Industry Context
This is a standard SEC filing for a publicly traded company, providing transparency and updates to investors regarding corporate governance, executive compensation, and related matters. The filing is specific to enGene Holdings Inc. and does not provide direct comparisons to industry trends or competitors.
Comparison to Industry Standards
- The document does not contain specific comparisons to industry standards.
- Executive compensation packages appear consistent with those offered to executives in similar biotechnology companies, including base salary, bonus potential, and equity awards.
- Corporate governance practices, such as the establishment of an audit committee, compensation committee, and nominating and corporate governance committee, are standard for publicly traded companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Jason D. Hanson | Ronald H.W. Cooper | July 22, 2024 | Hanson's resignation |
| Chief Medical Officer | NA | Raj S. Pruthi | July 22, 2024 | Promotion |
| Chief Scientific Officer | NA | Anthony T. Cheung | October 21, 2024 | New Role |
| Chief Technology Officer | Anthony T. Cheung | Joan Connolly | October 21, 2024 | New Role |
| Chief Strategy and Operations Officer | NA | Alexander Nichols | October 21, 2024 | New Role |
Related Party Transactions
- In February 2024, certain entities affiliated with Lumira Ventures, where director Gerald Brunk is a managing director, purchased 800,000 Common Shares for $8.0 million in a private placement.
- In October 2024, an entity affiliated with Forbion, where directors Jasper Bos and Wouter Joustra are general partners, purchased 561,797 Common Shares for approximately $5.0 million in a private placement.
Stakeholder Impact
- The information in this amendment provides greater transparency to shareholders regarding the company's leadership, governance, and compensation practices.
- The company's commitment to ethical business conduct and compliance with laws and regulations benefits all stakeholders.
- The company's retirement plans provide employees with an opportunity to save for retirement.
Key Dates
| Date | Description |
|---|---|
| December 9, 2021 | Date of Warrant Agreement between FEAC and Continental Stock Transfer & Trust Company. |
| April 10, 2020 | Date of Non-Exclusive License Agreement between enGene and Nature Technology Corporation. |
| November 11, 2019 | Date of Master Service Agreement between enGene and BioAgilytix Labs, LLC. |
| May 16, 2023 | Date of Business Combination Agreement among FEAC, enGene Inc., and enGene. |
| May 16, 2023 | Date of Sponsor and Insiders Letter Agreement among FEAC, the Sponsor, Forbion Growth Opportunities Fund I Cooperatief U.A., enGene Inc., enGene and the other parties named therein. |
| May 16, 2023 | Date of Letter Agreement among enGene, IQ, FEAC and enGene. |
| December 29, 2022 | Date of Lease Agreement between enGene and Are-Canada No. 5 Holdings, ULC. |
| April 24, 2023 | Dr. Richard M. Glickman has served as a member of enGenes Board since April 24, 2023. |
| August 8, 2023 | Jasper Bos, Ph.D. , has served as a member of the Board since August 8, 2023. |
| August 8, 2023 | Gerald Brunk has served as a member of enGenes Board since August 8, 2023. |
| September 13, 2023 | Date of Waiver and Consent Letter among FEAC, enGene Inc. and enGene Holdings Inc. |
| October 31, 2023 | Date of Registration Rights Agreement among enGene Holdings Inc., Forbion European Acquisition Corp. and each of the Holders identified therein. |
| October 31, 2023 | Date of Warrant Assignment, Assumption and Amendment Agreement, dated as of October 30, 2023, among FEAC, enGene Inc., enGene and Continental Stock Transfer & Trust Company |
| November 8, 2023 | Date of Employment Agreement between EnGene USA, Inc. and Jason D. Hanson. |
| November 27, 2023 | Ryan Daws has served as Chief Financial Officer and Head of Business Development of enGene since November 27, 2023. |
| November 29, 2023 | Date of Employment Agreement between enGene USA, Inc. and Richard Bryce. |
| December 13, 2023 | Date of Employment Agreement between enGene USA, Inc. and Ryan Daws. |
| December 18, 2023 | Lota Zoth has served as a member of the Board since December 18, 2023. |
| December 22, 2023 | Date of Amended and Restated Loan and Security Agreement among enGene Holdings Inc., enGene Inc. and enGene USA, Inc., as borrower, Hercules Capital, Inc., as agent, and the lenders from time to time party thereto. |
| January 29, 2024 | Lee G. Giguere has served as Chief Legal Officer and Corporate Secretary of enGene since January 29, 2024. |
| February 13, 2024 | Date of Transition and Modification Agreement between enGene USA, Inc. and Jason D. Hanson. |
| February 13, 2024 | Date of Form of Subscription Agreement, dated February 13, 2024 |
| April 9, 2024 | Dr. Raj S. Pruthi previously served as enGenes Senior Vice President, Urologic Oncology and Clinical Development from April 9, 2024 to July 22, 2024. |
| April 22, 2024 | Date of Employment Agreement between enGene USA, Inc. and Lee Giguere. |
| May 14, 2024 | Dr. Richard Glickman has served as chairman of the Board since May 14, 2024. |
| May 15, 2024 | Paul Hastings has served as a member of the Board since May 15, 2024. |
| May 15, 2024 | Wouter Joustra has served as a member of the Board since May 15, 2024. |
| July 22, 2024 | Ronald H.W. Cooper has served as Chief Executive Officer and as a director of enGene since July 22, 2024. |
| July 22, 2024 | Dr. Raj S. Pruthi has served as Chief Medical Officer of enGene since July 22, 2024. |
| July 22, 2024 | Date of Employment Agreement between enGene USA, Inc. and Ronald H. W. Cooper. |
| July 23, 2024 | Date of Amendment to Transition and Modification Agreement between enGene USA, Inc. and Jason D. Hanson. |
| July 22, 2024 | Date of Employment Agreement between enGene USA, Inc. and Raj Pruthi. |
| July 16, 2024 | Date of Transition Services Agreement and General Release, dated July 16, 2024, by and between enGene USA, Inc. and Richard Bryce |
| July 22, 2024 | Date of Inducement Grant Agreement, dated July 22, 2024, by and between enGene Holdings Inc. and Ronald H. W. Cooper |
| October 16, 2024 | Date of Amended and Restated Employment Agreement, dated October 16, 2024, by and between enGene USA, Inc. and Alexander Nichols |
| October 16, 2024 | Date of Separation and General Release Agreement, dated October 16, 2024, by and between enGene USA, Inc. and James Sullivan |
| October 21, 2024 | Date of Amended and Restated Employment Agreement, dated October 21, 2024, by and between enGene Inc. and Anthony T. Cheung |
| October 21, 2024 | Date of Employment Agreement, dated October 21, 2024, by and between enGene USA, Inc. and Joan Connolly |
| October 21, 2024 | Alexander Nichols has served as Chief Strategy and Operations Officer of enGene since October 21, 2024. |
| October 21, 2024 | Dr. Anthony T. Cheung currently serves as Chief Scientific Officer, a role he has held since October 21, 2024. |
| October 21, 2024 | Joan Connolly has served as Chief Technology Officer of enGene since October 21, 2024. |
| October 24, 2024 | Date of Form of Subscription Agreement, dated October 24, 2024 |
| December 18, 2024 | Date of First Amendment to Amended and Restated Loan and Security Agreement, dated December 18, 2024 |
| February 14, 2025 | The number of the registrants Common Shares outstanding as of February 14, 2025 was 50,977,560. |
| February 14, 2025 | As of February 14, 2025, the number of Common Shares subject to the Incentive Equity Plan was 9,809,943, inclusive of 2,626,397 Common Shares enGene is authorized to issue under the plan, plus 7,183,546 Common Shares that are subject to outstanding grants. |
| February 20, 2025 | Date of certifications of Principal Executive Officer and Principal Financial Officer. |
Keywords
corporate governance, executive compensation, directors, officers, financial statements, enGene Holdings, Form 10-K, amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.